YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
LOS ANGELES, October 05, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of an induc…
Puma Biotechnology PBYI announced that it has initiated the phase II ALISCA-Lung2 study evaluating its pipeline candidate, alisertib, in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The AL…
LOS ANGELES, September 17, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alis…
LOS ANGELES, September 09, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of…
It has been about a month since the last earnings report for Axsome Therapeutics (AXSM). Shares have lost about 3.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings r…
LOS ANGELES, September 03, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of indu…
Puma Biotechnology PBYI reported second-quarter 2026 adjusted earnings of 19 cents per share, beating the Zacks Consensus Estimate of 10 cents. In the year-ago quarter, the company had reported adjusted earnings of 15 cents per share. Tota…
Key Points Interested in Puma Biotechnology, Inc.? Here are five stocks we like better. Q2 performance improved: Puma Biotechnology reported $56.5 million in revenue and GAAP net income of $8.2 million, compared with a $3.8 million loss in…
Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, August 06, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the sec…
LOS ANGELES, August 05, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement…
The market expects Puma Biotech (PBYI) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's…
LOS ANGELES, July 23, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second qu…
LOS ANGELES, July 02, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement res…
Shares of Puma Biotechnology PBYI have witnessed a sharp increase in the past three months, driven by investor optimism surrounding the company's strong 2026 revenue outlook. The company's top line is primarily driven by sales of its sole…
LOS ANGELES, June 03, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement res…
Puma Biotechnology logo Key Points Interested in Puma Biotechnology, Inc.? Here are five stocks we like better. Puma reported Q1 2026 total revenue of $44.8 million (NERLYNX product revenue $42.0M) and a GAAP net loss of $3.8M, but raised…
Earnings Call Insights: Puma Biotechnology (PBYI) Q1 2026 MANAGEMENT VIEW * “Today, Puma reported total revenue for the first quarter of 2026 of $44.8 million,” said Founder, Chairman, President, CEO & Secretary Alan Auerbach, adding that…
Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, May 07, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first…
LOS ANGELES, May 06, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restr…
LOS ANGELES, April 23, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quart…
[Five stacks of coloured coins with a graph line above] Richard Drury A notable shift is underway in the small-cap market in 2026: profitable Russell 2000 companies are decisively outperforming their non-profitable counterparts, with profi…
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 3.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or…
LOS ANGELES, April 02, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement r…
Agios Pharmaceuticals (AGIO) shares soared 14.3% in the last trading session to close at $33.83. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.4% gain over…
On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securitie…
Shares of Puma Biotechnology PBYI have tanked 9.6% in the past month, reflecting the growing investor concern regarding the company’s soft 2026 revenue outlook. The company’s sole marketed product, Nerlynx (neratinib), is approved for trea…
Ironwood Pharmaceuticals IRWD and Puma Biotechnology PBYI are small-cap biotech firms that depend largely on the successful commercialization of a single key drug while trying to broaden their relatively limited pipelines. Each company con…
Puma Biotechnology PBYI reported fourth-quarter 2025 adjusted earnings of 29 cents per share, beating the Zacks Consensus Estimate of 24 cents. In the year-ago quarter, the company had reported adjusted earnings of 43 cents per share. The…
Puma Biotechnology logo Key Points Q4 2025 total revenue $75.5 million, driven by $59.9M in NERLYNX product revenue and a jump in royalty revenue to $15.6M, with roughly $5.7M of sales reflecting an inventory build at specialty pharmacies.…
LOS ANGELES, February 26, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all compar…
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.64 per share, beating the Zacks Consensus Estimate of $6.62 per share. This compares to earnings of $6.6 per share a year ago. These figures are adjusted for non-recurring…
LOS ANGELES, February 23, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of P…
LOS ANGELES, February 12, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fo…
Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items. This…
LOS ANGELES, February 04, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of induce…
As the U.S. market experiences a rebound with eased tensions over Greenland, key indices like the Dow Jones have seen significant gains, reflecting a positive shift in investor sentiment. In this dynamic environment, identifying promising…